Answers are grounded in this paper and cite their sources.
Oral candidiasis is an opportunistic fungal infection that typically affects immunocompromised patients and is caused by yeasts of the genus Candida. Although Candida albicans is the primary etiological agent of oral candidiasis, non-albicans species, such as C. tropicalis and C. glabrata, have been frequently isolated from individuals with this disease. The goal of the present study was to assess the antifungal activity of isoeugenol, determine its effect on the micromorphology of the mouth isolates C. tropicalis and C. glabrata and observe its combined effect with the standard antifungal medication nystatin. The antifungal activity of isoeugenol was tested using the broth microdilution method, and its effect on the micromorphology of pathogenic structures (blastoconidia and pseudohyphae) of C. tropicalis was also assessed. The fractional inhibitory concentration index (FICI) of isoeugenol and nystatin was determined using the checkerboard method. The results showed that isoeugenol had an antifungal effect, with minimum inhibitory concentrations (MICs) ranging from 128 to 256 µg/mL for C. tropicalis and C. glabrata. The minimum fungicidal concentration (MFC) of isoeugenol ranged from 128 to 512 µg/mL for C. tropicalis and from 128 to 256 µg/mL for C. glabrata. In addition, isoeugenol altered the micromorphology of the analyzed fungal isolates. The combination of isoeugenol and nystatin showed synergistic activity against C. tropicalis LM-211 (FICI=0.25). The results of this study revealed that isoeugenol is a phytochemical with effective antifungal activity against Candida spp. and has a high potential for use as an antifungal medication.
No takes yet. Share an insight, caveat, or question.
Medeiros et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: